painreform.com - רווח החברה לפני מסים, ריבית ופחת PRFX
PainReform Ltd. (PRFX) management is focusing on refining formulas while currently generating no sales. The EBITDA figure as of today illustrates the results of this strategy, where the 0.00 level reflects the status of the parameter. The innovative drug PRF-110 reduces the need for opioids by providing a three-day effect. However, geopolitical instability and sanctions on raw materials create risks for supply chains and patent protection.
פילוחי נתונים אנליטיים מרוכזים עבור PainReform (PRFX)
PainReform Ltd. (PRFX) is developing long-acting analgesics for hospitals aimed at replacing opioids, which defines the potential for revenue scaling. An analysis of absolute operating profit allows for an assessment of the actual cash flow from these activities without the influence of debt load, while the absolute operating profit trend on this chart serves as an indicator of production asset efficiency across different cycle phases.
